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worse left behind, or in normal tissues, 
remains unclear. Further, the study 
does not address the issue of hetero-
geneity within the same sample.
There is also a need to correlate 
the findings with clinicopathological 
features and to be able to carry out 
subset analysis, in particular expand-
ing the analysis of the high-grade/
high-p16/high-Ki67 DCIS. This issue 
also highlights very clearly that a 
combination of pathological, clinical, 
and molecular factors may ultimately 
reveal more powerful and robust mea-
sures for disease classification than 
any one modality alone (Rosai, 2007).
The ability to predict the outcome 
of an in situ cancer at the time of pri-
mary diagnosis would make a huge 
impact in clinical practice, especially 
as the frequency of the lesions is rising 
due to mammographic screening. The 
authors have set the stage for DCIS, 
which is generally a segmental disease 
(Figure 1). Perhaps this will also be the 
spur to study lobular carcinoma in situ 
(LCIS), a multifocal proliferation with 
a bilateral risk of invasive carcinoma, 
and hence an even bigger dilemma 
regarding appropriate management.
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Constitutive signaling by the NOTCH1 receptor contributes to more than half of all cases of T cell 
acute lymphoblastic leukemia (T-ALL). However, blocking the proteolytic activation of NOTCH1 with 
γ-secretase inhibitors (GSIs) fails to alter the growth of some T-ALL cell lines carrying the mutated 
receptor. A recent report by Palomero et al. in Nature Medicine identifies loss of PTEN as a critical 
event leading to resistance to NOTCH inhibition, which causes the transfer of “oncogene addiction” 
from the NOTCH1 to the PI3K/AKT pathway. This novel observation suggests the need to simultane-
ously inhibit both pathways as a means to improve therapeutic efficacy in human T-ALL.NOTCH1 encodes a transmembrane 
receptor that undergoes a series of 
activation steps upon ligand binding, 
culminating in the γ-secretase-medi-
ated proteolytic release of the intra-
cellular fragment of NOTCH1 (ICN). 
The ICN then translocates to the 
nucleus, where it is transcriptionally 
active and required for T cell devel-
opment (reviewed in Grabher et al., 
2006). Aberrant NOTCH1 activation 
leads to T-ALL in the mouse, and activating mutations occur in more 
than 50% of cases of human T-ALL 
(Weng et al., 2004). GSIs, which were 
initially developed for the treatment of 
Alzheimer’s disease, effectively inhibit 
the proteolytic activation of NOTCH 
receptors, a discovery that led to 
enthusiastic application of NOTCH 
pathway inhibitors to block cell pro-
liferation and survival in T-ALL. Inhi-
bition of NOTCH1 signaling by GSI 
treatment proved effective in induc-Cancer Cell 12, Ning proliferation arrest or apoptosis in 
some but not all T-ALL cell lines, sug-
gesting a previously unrecognized 
mechanism of resistance. In a recent 
report in Nature Medicine, Palomero 
et al. (2007) show that homozygous 
loss of PTEN is a critical determinant 
of resistance to GSI-mediated inhi-
bition of NOTCH1 signaling in T-ALL 
cell lines (Figure 1). They show fur-
ther that PTEN expression is nega-
tively regulated by HES1, a prominent ovember 2007 ©2007 Elsevier Inc. 411
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Previewsfigure 1. PTEN Inactivation Leads to Resistance to nOTcH1 Inhibition but Depen-
dence on AKT signaling
(A) T-ALL lymphoblasts with activating mutations of NOTCH1 constitutively generate intracellular 
NOTCH1 (ICN), whose transcriptional targets include MYC and HES1. MYC is a transcriptional 
activator of PTEN, but HES1-mediated repression appears to predominate under ICN signaling 
conditions. Low expression of PTEN leads to incomplete inhibition of the PI3K-AKT pathway. 
(B) Inhibition of proteolytic release of ICN from the NOTCH1 receptor by γ-secretase inhibitors 
(GSIs) blocks ICN-mediated proliferative and survival signals, leading to cell cycle arrest and 
apoptosis. Additionally, the HES1-mediated repression of PTEN expression is relieved, and PTEN 
can therefore inhibit prosurvival signaling mediated by the PI3K-AKT pathway. Thus, PTEN-posi-
tive T-ALL cells with activating NOTCH1 mutations depend on NOTCH1 activity for survival and 
proliferation. 
(C and D) In the absence of PTEN, uninhibited AKT activation leads to aberrant prosurvival and 
proliferative signaling independent of NOTCH1 pathway activity, thus leading to resistance to 
NOTCH1 inhibition. As previewed in this article, Palomero et al. show that PTEN null T-ALL cells 
that are resistant to NOTCH1 inhibition are “addicted” to PI3K/AKT pathway signaling.downstream target of NOTCH1. Pre-
sumably, the NOTCH1-HES1-medi-
ated conditional inhibition of PTEN can 
become constitutive through PTEN 
mutation or deletion, which renders 
the cells resistant to GSIs by prevent-
ing the reactivation of PTEN that typi-
cally occurs when NOTCH signaling is 
blocked. Interestingly, the acquisition 
of resistance to NOTCH1 inhibition 
via PTEN loss transfers the malignant 
clone’s “oncogene addiction” from 
the NOTCH pathway downstream 412 Cancer Cell 12, November 2007 ©200to constitutively activated PI3K-AKT 
signaling, which is normally inhibited 
by PTEN.
These findings have clear implica-
tions for the treatment of T-ALL, as 
they provide a firm rationale for the 
use of combination therapy targeting 
both the NOTCH1 and the PI3K-AKT 
pathways. A number of inhibitors of 
various proteins within the PI3K-AKT 
pathway are currently under clinical 
development (Hennessy et al., 2005). 
Although the optimal PI3K-AKT path-7 Elsevier Inc.way inhibitor, or combination of inhib-
itors, for the treatment of T-ALL is 
unknown, the data of Palomero et al. 
suggest that direct inhibition of AKT 
is likely to be effective in T-ALL cases 
harboring PTEN mutations. Addition-
ally, the inhibition of mTOR, a down-
stream effector of AKT signaling, was 
recently shown to be synergistic with 
γ-secretase inhibition in T-ALL cell 
lines, whether or not the lines were 
sensitive to GSIs alone (Chan et al., 
2007). The inhibition of other gene 
products in the PI3K-AKT pathway 
in combination with GSI treatment 
may prove to be similarly synergis-
tic. Finally, a myriad of PI3K-AKT 
pathway mediators and members of 
interacting pathways are mutated in 
human cancer, suggesting the need 
for additional molecular analysis of T-
ALL cases that lack PTEN abnormali-
ties (Brugge et al., 2007).
An important question raised by 
the work of Palomero et al. is whether 
the NOTCH1 and PI3K-AKT signaling 
pathways share a common effector 
that represents the “core” of the onco-
genic stimulus in T-ALL. MYC comes 
to mind immediately because of its 
status as a prominent downstream tar-
get of NOTCH1 signaling in human and 
murine T-ALL (Palomero et al., 2006; 
Sharma et al., 2006; Weng et al., 2006), 
the demonstration of addiction to MYC 
in a wide range of experimental tumor 
models (reviewed in Arvanitis and 
Felsher, 2005), and the involvement 
of AKT signaling in MYC activation 
through the inhibition of GSK3β-medi-
ated inactivation of the MYC protein. 
Thus, MYC could mediate the addiction 
of leukemic T cells to both NOTCH1 and 
AKT signaling. Interestingly, two recent 
reports have documented dominant-
negative FBW7 mutations in many of 
the same GSI-resistant T-ALL cell lines 
that were shown by Palomero et al. to 
harbor PTEN mutations (O’Neil et al., 
2007; Thompson et al., 2007). Since 
FBW7 is the recognition component 
of an E3 ubiquitin ligase that normally 
targets both MYC and the NOTCH ICN 
for proteasomal degradation, it is pos-
sible that PTEN mutations and FBW7 
mutations synergize to render malig-
nant clones independent of NOTCH1 
signaling for growth and survival. Fur-
ther studies are needed to identify 
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pressure that exists in T-ALL cells with 
NOTCH1 mutations, which results in 
the outgrowth of malignant clones that 
harbor inactivating mutations of both 
PTEN and FBW7.
One of the most intriguing questions 
raised by this work is whether interac-
tions between the NOTCH and PI3K/
AKT pathways occur in other types of 
human cancers. If so, the discovery by 
Palomero et al. and its implications for 
targeted therapy could have far-reach-
ing consequences.
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